N-Acetyl-Epithalon Moderate Evidence

What It Is

N-Acetyl-Epithalon — also written as Acetyl-Epitalon Amidate, Ac-Epitalon-NH₂, Ac-AEDG-NH₂, or simply "modified Epithalon" — is a chemically protected analog of Epithalon (Epitalon), the synthetic tetrapeptide alanyl-glutamyl-aspartyl-glycine (Ala-Glu-Asp-Gly, AEDG) that has been the central research compound of the Khavinson school of peptide bioregulation for more than three decades. The parent compound Epithalon was synthesized in the 1990s based on the amino-acid composition of Epithalamin, a polypeptide complex isolated from bovine pineal gland that had been clinically evaluated in the Soviet Union since the late 1970s as a putative geroprotector. The N-Acetyl-Epithalon variant takes the same four-residue backbone and protects both ends of the peptide chain — the N-terminus is acetylated (an acetyl group covalently attached to the alanine alpha-amino group) and the C-terminus is amidated (the glycine carboxylate replaced with a carboxamide). The result is a peptide approximately 432 daltons in molecular weight that is chemically more peptidase-resistant than the unprotected parent Epithalon (~390 Da).

The Khavinson research program — based at the St. Petersburg Institute of Bioregulation and Gerontology of the Russian Academy of Medical Sciences and led for decades by Vladimir Khavinson, Vladimir Anisimov, and a network of long-standing collaborators — has produced more than a hundred publications across cell culture, animal models, and human elderly cohorts on parent Epithalon and the broader family of Khavinson short peptides. Their central thesis is that ultra-short bioregulator peptides (di-, tri-, and tetrapeptides derived from tissue extracts) penetrate cellular and nuclear membranes, bind specific DNA sequences in promoter regions, and modulate transcription of genes involved in tissue-specific homeostasis and aging. Epithalon has been the most extensively characterized member of this family and the prototype example of the proposed transcription-modulation mechanism.

The acetylation and amidation modifications that produce N-Acetyl-Epithalon are routine medicinal-chemistry strategies used across peptide pharmacology to improve metabolic stability. Free peptides with unprotected termini are rapidly degraded in plasma by aminopeptidases (which trim residues from the N-terminus) and carboxypeptidases (which trim from the C-terminus); blocking either end can extend plasma half-life by an order of magnitude or more. For parent Epithalon, the published plasma half-life is on the order of minutes — consistent with rapid proteolytic clearance. The acetyl-amidate modification is intended to push that into the hours range, allowing less frequent administration and providing more sustained tissue exposure for the proposed transcription-modulation mechanism.

Importantly, the publicly available peer-reviewed literature on the acetyl-amidate variant specifically is much thinner than on parent Epithalon. The compound is marketed and sold by research-peptide suppliers worldwide, and its mechanistic claims are extrapolated from the parent peptide's literature. The honest framing for a research user is: N-Acetyl-Epithalon inherits the (largely Khavinson-group) evidence base of parent Epithalon, with a pharmacokinetic upgrade that is biochemically reasonable but not independently characterized in detail in peer-reviewed western pharmacokinetic studies. This is the central caveat that should accompany any reading of the proposed activity.

Mechanism of Action

The mechanistic claims for N-Acetyl-Epithalon are inherited almost entirely from the parent Epithalon literature, with the additional layer that acetyl-amidate modification extends biological half-life and tissue exposure. The proposed mechanism set, drawn primarily from Khavinson-group cell culture and animal work plus a handful of independent replications, is as follows:

• Telomerase reverse transcriptase (hTERT) gene-expression induction — The defining mechanistic claim of the parent Epithalon literature. Khavinson, Bondarev, and Butyugov reported in 2003 (Bull Exp Biol Med, PMID 12937682) that Epithalon treatment of cultured human somatic cells (fetal fibroblasts) increased expression of the catalytic subunit of telomerase (TERT) and induced enzymatic telomerase activity in cells that were previously telomerase-negative. The acetyl-amidate variant is proposed to access the same nuclear targets with longer residence time. A 2025 independent paper (Araj et al.) revisited this question in human cell lines and reported that Epitalon increases telomere length via telomerase upregulation in normal cells and via the alternative lengthening of telomeres (ALT) pathway in cancer cell lines — adding nuance to the original model.
• Telomere length maintenance / elongation — As a downstream consequence of telomerase activation, parent Epithalon has been reported in cell culture to extend telomere length and to push fetal fibroblast cultures past the Hayflick limit (extending proliferative capacity from the standard ~34 passages to beyond 44). These claims have been replicated in part (Araj et al. 2025) but should be interpreted with caution — telomere measurement methodology has matured significantly since the original 2003 reports, and not all of the early findings have been re-tested with current TRF Southern, qPCR, and STELA techniques.
• Pineal axis / melatonin secretion modulation — Parent Epithalon and parent extract Epithalamin both restore the nocturnal melatonin peak in cultured pinealocytes and in aged animals. The proposed downstream effect is normalization of circadian rhythm in aged subjects whose pineal output has declined — a phenomenon documented in rhesus monkey studies by the Khavinson group and in elderly human trials of parent Epithalamin.
• Antioxidant defense gene upregulation — Pineal peptide bioregulators including parent Epithalon have been reported to upregulate antioxidant enzyme activity, with rat studies documenting increased activity of superoxide dismutase (SOD), glutathione peroxidase, and glutathione-S-transferase (Kozina, Arutjunyan, Khavinson, Arch Gerontol Geriatr 2007, PMID 17317455). The antioxidant signal in some assays exceeded that of melatonin itself.
• Chromatin-binding / direct gene-expression modulation — Khavinson's broader hypothesis is that ultra-short peptides penetrate the nucleus, bind specific DNA sequences in promoter regions (often via interactions with the methylated cytosines of CpG islands), and directly modulate transcription. Fedoreyeva, Kireev, Khavinson, and Vanyushin (Biochemistry Moscow 2011, PMID 22117545) demonstrated penetration of fluorescence-labeled short peptides into the HeLa cell nucleus and characterized in vitro specific peptide–DNA interactions. The 2020 Khavinson/Diomede paper in Molecules (PMID 32019204) extended this work to AEDG peptide effects on neurogenic gene expression in human gingival mesenchymal stem cells, proposing histone-binding as part of the mechanism.
• Anti-apoptotic / proliferation-supporting signaling — In cultured cells, parent Epithalon supports survival signaling and reduces age-associated apoptotic cell loss. The Khavinson group has reported anti-apoptotic effects across multiple tissue-derived peptide bioregulators.
• Immunomodulation in aged organisms — In aged rodent models, parent Epithalon and the related thymic peptide Thymalin restore immune function markers — T-cell subset balance, NK activity, antibody response — toward younger-animal baselines. The signaling pathways linking AEDG peptide to immune-cell gene expression are proposed but not fully characterized.
• Tumor-incidence reduction in animal models — Parent Epithalon, administered to female SHR mice on a 5-days-per-month schedule from age 3 months, reduced incidence of spontaneous mammary tumors and chromosomal aberrations and decelerated reproductive senescence (Anisimov, Khavinson et al., Biogerontology 2003). This finding is mechanistically interesting because it pairs with the telomerase activation claims — telomerase reactivation is normally regarded as oncogenic, but this animal data suggested net antitumor activity at the doses and dosing schedule used.
• Acetyl-amidate pharmacokinetic enhancement — The N-terminal acetyl group sterically and electronically blocks aminopeptidase recognition; the C-terminal amide blocks carboxypeptidase recognition. Both modifications are routine in peptide medicinal chemistry and are documented across many examples to extend plasma half-life. For N-Acetyl-Epithalon specifically, peer-reviewed pharmacokinetic studies are limited, and most claims about extended half-life are extrapolated from analogous peptide modifications rather than measured directly.
• Multi-tissue gene-expression effects — DNA microarray studies of AEDG peptide effects on mouse heart tissue (Anisimov SV, Boheler, Khavinson, Anisimov VN, Bull Exp Biol Med 2002) reported modulation of multiple gene clusters, supporting the general hypothesis that the peptide acts as a transcription-modulating agent rather than a single-receptor ligand.

What the Research Shows

Research findings for N-Acetyl-Epithalon must be read in two layers: (1) the substantial parent Epithalon evidence base from which the acetyl-amidate variant inherits its mechanistic and clinical positioning, and (2) the much thinner direct evidence on the acetyl-amidate compound itself, which is largely absent from the indexed peer-reviewed literature and circulates instead through research-supplier marketing materials and analog inference.

• Telomerase activation in human somatic cells — The 2003 Khavinson/Bondarev/Butyugov paper (Bull Exp Biol Med, PMID 12937682) is the seminal in-vitro finding: Epithalon treatment of cultured human fetal fibroblasts induced TERT expression and detectable telomerase activity in previously telomerase-negative cells, with downstream telomere elongation. This is the single most-cited Epithalon paper and the foundation of the compound's longevity-research positioning.
• Hayflick-limit extension in fibroblast culture — Subsequent Khavinson-group work in human fetal fibroblasts reported extension of replicative capacity beyond the standard Hayflick limit with sustained Epithalon exposure — fibroblast cultures continued dividing past passage 44 versus the typical termination at passage 34 in untreated controls.
• Modern independent replication (Araj et al. 2025) — A 2025 paper revisited Epitalon in modern human cell lines and reported that the peptide increases telomere length via two mechanisms: telomerase upregulation in normal cells, and ALT (alternative lengthening of telomeres) activation in cancer cell lines. This is independent (non-Khavinson) replication of the core telomere-lengthening claim using contemporary methodology, with a nuance that suggests the ALT-activation in cancer cells specifically is a meaningful safety consideration.
• Pineal axis and melatonin restoration in aged primates — In rhesus monkeys with age-related decline of nocturnal melatonin secretion, parent Epithalon administration restored a normal circadian melatonin profile (Khavinson, Goncharova, Lapin reports). Similar findings were reported in elderly human cohorts treated with parent Epithalamin.
• Antioxidant enzyme upregulation in aged rats — Kozina, Arutjunyan, Khavinson (Arch Gerontol Geriatr 2007, PMID 17317455) reported that pineal peptide preparations (Epithalamin and Epitalon) possess antioxidant properties in aged rat tissue exceeding in some cases the ROS-scavenging effect of melatonin itself.
• Lifespan extension in mice — SHR mouse trial — Anisimov, Khavinson, Popovich and colleagues (Biogerontology 2003) administered Epitalon (1 µg/mouse, ~30–40 µg/kg) subcutaneously on 5 consecutive days per month from age 3 months until natural death in female outbred Swiss-derived SHR mice. The treated group showed delayed reproductive senescence (later age-related estrous shutdown), reduced incidence of bone-marrow chromosome aberrations (~17% reduction), and reduced incidence of spontaneous mammary tumors. Mean lifespan was modestly extended depending on the strain and protocol.
• Lifespan extension in Drosophila — Khavinson and Mylnikov reported that Epithalon administered to wild-strain Drosophila melanogaster extended mean lifespan of imagoes by 11–16% across both sexes, with the effect concentrated in mature and old flies.
• Tumor-incidence reduction in transgenic HER-2/neu mice — Anisimov, Khavinson et al. (Int J Cancer 2002, PMID 12209581) reported that Epitalon administration to HER-2/neu transgenic mice (a high-incidence mammary cancer model) inhibited spontaneous mammary tumor development, possibly via downregulation of HER-2/neu mammary adenocarcinoma gene expression.
• Retinitis pigmentosa pilot — Parent Epithalon was studied in Campbell rats (a model of hereditary retinitis pigmentosa) and prolonged the functional integrity of the eye retina; a small clinical trial in human retinitis pigmentosa patients at the St. Petersburg Institute reported positive clinical effect in approximately 90% of treated cases by visual function assessment (Khavinson and colleagues; Neuro Endocrinol Lett 2002).
• Elderly cardiovascular and immune normalization — Korkushko, Khavinson, Shatilo et al. evaluated parent Epithalamin and Thymalin in 266 elderly subjects over a 6–8 year follow-up, reporting normalization of cardiovascular, endocrine, immune, and nervous system indices and improvement in homeostasis and metabolism (Adv Gerontol 2002, PMID 12577695; Neuro Endocrinol Lett 2003, PMID 14523363). A 15-year follow-up extension reported by the Korkushko group described continued geroprotective effects in survivors.
• Neurogenesis and stem-cell differentiation — Khavinson, Diomede, Mironova et al. (Molecules 2020, PMID 32019204) reported that AEDG peptide stimulates gene expression and protein synthesis during neurogenesis in human gingival mesenchymal stem cells, with histone-binding proposed as the mechanism. This suggests potential broader regenerative-medicine applications beyond pineal-axis modulation.

Human Data

Direct human data on N-Acetyl-Epithalon specifically (the acetyl-amidate variant) is absent from the indexed peer-reviewed literature. The relevant human evidence base is the Khavinson-group human studies of parent Epithalon and the parent extract Epithalamin, from which the acetyl-amidate variant inherits its clinical positioning. Honest framing: the human evidence is single-lineage, modest in sample sizes, and not independently replicated by western multicenter RCTs.

• Korkushko, Khavinson, Shatilo et al. (Adv Gerontol 2002, PMID 12577695) — Geroprotective effect of Thymalin and Epithalamin in 266 elderly and older persons, 6–8 year follow-up. Reported normalization of cardiovascular, endocrine, immune, and nervous system indices. Note: this is parent Epithalamin (the polypeptide complex), not synthetic AEDG/Epithalon.
• Khavinson, Morozov (Neuro Endocrinol Lett 2003, PMID 14523363) — "Peptides of pineal gland and thymus prolong human life." Long-form review of the same 266-subject cohort, with discussion of mortality reduction in the treated group across the multi-year follow-up. Khavinson-group authorship; not independently audited.
• Khavinson, Trofimova et al. (retinitis pigmentosa pilots, ~2002–2010) — Small clinical trials of parent Epithalon in human retinitis pigmentosa patients at the St. Petersburg Institute of Bioregulation and Gerontology, reporting positive visual-function effect in approximately 90% of treated subjects. Sample sizes small; not placebo-controlled multicenter design.
• Russian Academy of Sciences elderly cohort (Anisimov reports) — Anisimov has described informally that daily injection of 1–3 mg Epithalon for 10 days every 3 months administered to the elderly members of the Russian Academy of Sciences reduced mortality in this assembly by 30–50% over a 7-year follow-up period. This is reported as observational geroprotector data rather than as an RCT and is part of the broader Khavinson-group lifespan literature.
• Pulmonary tuberculosis chromosomal-aberration trial — A small human clinical study in pulmonary tuberculosis patients reported that Epitalon did not correct pre-existing structural chromosomal aberrations associated with telomere degradation but appeared to exert a protective effect against future development of additional aberrations. Mechanism interpretation: telomere-length maintenance prevents accumulation of new abnormalities even where existing damage is fixed.
• Telomere length in elderly blood cells — Khavinson-group human studies have reported that both Epitalon and Epithalamin significantly increased telomere lengths in blood cells of patients aged 60–65 and 75–80, with comparable efficacy between the synthetic peptide and the parent extract. Methodology and assay platform should be examined critically in light of contemporary telomere-measurement standards.
• Korkushko 15-year follow-up extension (Bull Exp Biol Med 2011) — Long-form follow-up of the elderly cohort treated with peptide geroprotector(s), reporting deceleration of cardiovascular system aging, prevention of age-associated impairment of physical endurance, normalization of circadian melatonin secretion, and normalization of carbohydrate and lipid metabolism over the multi-year observation window. Khavinson-group authorship.
• N-Acetyl-Epithalon variant — direct human data — Not published in the indexed peer-reviewed literature. Use is essentially extrapolative. Clinical claims for the acetyl-amidate compound rest on the parent Epithalon evidence base plus the biochemical rationale that improved peptidase resistance should yield comparable or improved tissue exposure at lower or less frequent doses.

The honest summary: there is enough Khavinson-group human data on parent Epithalon to take the geroprotector hypothesis seriously as a research question, but not enough independently replicated multicenter RCT data to claim established clinical efficacy. The N-Acetyl-Epithalon variant specifically has even less direct human characterization. A research user is choosing to engage a hypothesis, not a proven intervention.

Dosing from the Literature

Direct dosing literature for N-Acetyl-Epithalon specifically is sparse. The dosing patterns below are extrapolated from parent Epithalon clinical use (Khavinson-group protocols) plus community-research-literature reports for the acetyl-amidate variant. The pharmacokinetic upgrade conferred by acetyl-amidate modification is generally invoked to justify either lower per-dose amounts or longer dosing intervals, though the specific dose-equivalence relationship has not been formally established in published comparative pharmacokinetic studies.

Reconstitution & Storage

N-Acetyl-Epithalon is supplied lyophilized in vials of 5, 10, 20, and occasionally 40 mg. Reconstitution uses bacteriostatic water for injection (BAC water, 0.9% benzyl alcohol). The acetyl-amidate modification confers improved aqueous-solution stability versus parent Epithalon, but the practical research-use shelf-life envelope is similar — 28 days at 2–8°C reconstituted, with the dry lyophilized vial stable long-term at −20°C protected from light.

Units refer to standard insulin syringe (U-100): 100 units = 1.0 mL.

• Reconstitution technique — Slowly inject BAC water down the side of the vial (not directly onto the lyophilized cake). Swirl gently — do not shake. Allow the cake to dissolve without agitation. Vigorous shaking can fragment the peptide and reduce potency.
• Lyophilized vial storage — Stable long-term at −20°C protected from light. Dry vials ship at ambient temperature without significant degradation if the transit window is short (under 7 days).
• Reconstituted vial storage — 2–8°C (refrigerated) for approximately 28 days. Discard if any visible cloudiness, color change, or particulate appears.
• Light protection — Store both lyophilized and reconstituted vials away from direct light. Aluminum-foil wrap is standard practice for refrigerated reconstituted vials.
• Compatibility — N-Acetyl-Epithalon is not co-formulated with other peptides in the same vial. If stacking with parent Epithalon or other Khavinson short peptides, use separate injection sites.
• Injection site — Subcutaneous administration in abdominal or thigh tissue is the most common research-use route. Rotate sites to avoid lipohypertrophy with repeated cycles.

→ Use the Kalios Dosing Calculator for reconstitution math

Side Effects & Risks

The published safety signal for N-Acetyl-Epithalon and parent Epithalon is very limited — concentrated in the Khavinson-group literature, which consistently describes the compounds as well-tolerated with minimal adverse-event reporting. There is no large-scale pharmacovigilance database equivalent to what exists for FDA-approved drugs. The primary risks are theoretical and arise from the proposed mechanism rather than from observed adverse-event reporting:

• Telomerase reactivation and oncogenicity question — The single most important theoretical concern. Telomerase reactivation is a hallmark of approximately 85–90% of human cancers — most malignant cells have telomerase activity to escape replicative senescence. A compound proposed to induce telomerase activity in normal somatic cells raises a legitimate question about whether chronic exposure could increase cancer incidence over a multi-decade time horizon. The Khavinson-group animal data paradoxically shows reduced spontaneous tumor incidence in treated mice (Anisimov, Khavinson et al. 2003; Anisimov et al. Int J Cancer 2002, PMID 12209581), and the 2025 Araj et al. paper noted that Epitalon activates the ALT pathway specifically in cancer cells (not normal cells) — but the question of long-term oncogenicity in humans has not been resolved by long-term human surveillance data, and a research user should regard this as the central uncertainty.
• Unknown impact on existing malignancy — In a person with an undiagnosed early-stage malignancy or a cancer-prone genetic background, the theoretical consequences of telomerase induction are different from those in a healthy aging adult. Caution is appropriate; baseline cancer screening and family-history awareness should precede any cycle.
• Limited human safety surveillance — There is no large multicenter prospective adverse-event registry for parent Epithalon or any acetyl-amidate variant. Safety claims rely on Khavinson-group reports, which have generally described the compounds as well-tolerated but have not been audited by independent regulators or published in a format comparable to FDA-required post-marketing surveillance data.
• Purity and identity concerns — N-Acetyl-Epithalon is sold by research-peptide suppliers worldwide. Purity, peptide content per vial, and exact chemical identity (whether the N-terminal acetyl and C-terminal amide modifications are both present and complete versus partial or absent) are not subject to the FDA / EMA quality controls applied to approved pharmaceuticals. Independent third-party testing — HPLC purity, mass-spec identity confirmation — is the practical floor for any research user. Suppliers vary widely.
• Allergic / hypersensitivity reactions — Rare but biologically plausible for any injected peptide. Local reactions at the injection site (erythema, mild induration) have been reported anecdotally with parent Epithalon and would be expected to occur with similar frequency for the acetyl-amidate variant.
• Drug interactions — Not formally characterized in any peer-reviewed pharmacology study. Theoretical interactions with cancer chemotherapy (which often targets dividing cells via mechanisms that interact with telomere biology), with other longevity-targeted interventions (NAD+ precursors, rapamycin, senolytics), and with melatonin or other circadian-axis modulators have not been systematically studied.
• Endocrine modulation — Pineal-axis modulation could theoretically affect melatonin, cortisol, and downstream gonadotropin signaling. In aged subjects with low baseline melatonin, normalization may be desirable; in subjects with normal pineal function, the directionality of the effect is less clear.
• WADA / sport-anti-doping caution — N-Acetyl-Epithalon is not specifically named on the WADA Prohibited List as of the most recent published revision. However, peptides with claims to growth-factor-like or repair-signaling activity are subject to scrutiny under broader S-class categories. Athletes subject to WADA testing should consult their sport-specific federation and consider that the compound's regulatory status could shift without notice.
• Pregnancy and lactation — No safety data. Avoid.
• Pediatric use — No safety data. Not appropriate for pediatric administration outside a formal investigational protocol.
• Long-term cumulative exposure — Unknown. The Khavinson-group cycling protocols (10–20 day courses 1–2× per year) implicitly limit cumulative exposure; users who deviate to more frequent or continuous dosing schedules are operating outside the published evidence base entirely.

Bloodwork & Monitoring

No specific bloodwork protocol has been published for N-Acetyl-Epithalon. The recommended monitoring framework is built from baseline-and-cycle bloodwork principles plus age-appropriate cancer screening given the telomerase-activation mechanism:

• Baseline CBC and CMP — Standard pre-cycle complete blood count and comprehensive metabolic panel. Establishes baseline hematologic and metabolic status before initiating any peptide cycle.
• Baseline lipid panel — Optional but useful given parent Epithalamin reports of metabolic / lipid normalization in elderly cohorts.
• IGF-1 — Useful as a general marker of growth-factor axis status when stacking with other longevity-targeted compounds.
• Melatonin / cortisol if circadian symptoms present — Salivary or blood melatonin (nocturnal sample) and a 4-point cortisol curve can document baseline pineal-axis status if circadian disruption is part of the use rationale.
• Age-appropriate cancer screening — Given the telomerase-activation mechanism and the unresolved long-term oncogenicity question, age-appropriate screening should be current before initiating cycling: colonoscopy per national guideline schedule, mammogram / breast exam, prostate exam and PSA where applicable, full-body skin exam, and any indicated follow-up on family-history-driven screens (BRCA, Lynch, etc.). This is harm-reduction framing, not evidence-based efficacy guidance.
• End-of-cycle CBC, CMP, lipid panel — Repeat baseline labs at the conclusion of a cycle to document any deltas. If any unexpected change appears, hold further cycling and investigate.
• Annual or biannual full panel during ongoing cycling — For users who cycle 1–2× per year, an annual comprehensive panel (CBC, CMP, lipids, HbA1c, fasting insulin, IGF-1, hsCRP, vitamin D, thyroid panel) provides longitudinal trend data for the broader longevity context.
• Symptom-driven re-evaluation — Any new symptom that could plausibly relate to occult malignancy (unexplained weight loss, persistent lymphadenopathy, change in bowel habits, abnormal bleeding) should prompt immediate clinical evaluation rather than continuation of cycling.
• Telomere length measurement — Available commercially (TeloYears and similar services). Methodologically variable across providers; useful as a longitudinal personal trend rather than a clinical decision-making tool.

Commonly Stacked With

N-Acetyl-Epithalon is most commonly used as part of a longevity / pineal-axis stack rather than as monotherapy. The most frequent pairings reflect the Khavinson family of peptide bioregulators plus complementary longevity-targeted interventions.

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

People looking at N-Acetyl-Epithalon usually compare with these:

Next Steps

Key References

1. Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. PMID: 12937682. (The seminal in-vitro telomerase induction finding for parent Epithalon — fetal fibroblast TERT expression and telomere elongation.)
2. Anisimov VN, Khavinson VK, Popovich IG, Zabezhinski MA, Alimova IN, Rosenfeld SV, Zavarzina NY, Semenchenko AV, Yashin AI. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202. (108 SHR mice; 5-days-per-month subcutaneous Epitalon from age 3 months until natural death; reduced chromosome aberrations, delayed reproductive senescence, reduced spontaneous tumor incidence.)
3. Anisimov VN, Khavinson VK, Provinciali M, Alimova IN, Baturin DA, Popovich IG, Zabezhinski MA, Imyanitov EN, Mancini R, Franceschi C. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int J Cancer. 2002;101(1):7-10. PMID: 12209581. (HER-2/neu transgenic mammary cancer model; Epitalon reduced spontaneous mammary tumor development, possibly via HER-2/neu downregulation.)
4. Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240. PMID: 14523363. (Khavinson-group review of the 266-subject elderly cohort treated with Thymalin and Epithalamin over 6–8 years; reported mortality reduction and multi-system normalization.)
5. Khavinson VK. [Geroprotective effect of thymalin and epithalamin]. Adv Gerontol. 2002;9:80-87. PMID: 12577695. (Russian-language clinical assessment of geroprotective effects of the two peptide bioregulators in 266 elderly subjects; cardiovascular, endocrine, immune, and nervous system normalization.)
6. Kozina LS, Arutjunyan AV, Khavinson VK. Antioxidant properties of geroprotective peptides of the pineal gland. Arch Gerontol Geriatr. 2007;44 Suppl 1:213-216. PMID: 17317455. (Pineal peptide preparations including Epitalon possess antioxidant properties exceeding melatonin's in some assays; aged-rat tissue.)
7. Khavinson V, Diomede F, Mironova E, Linkova N, Trofimova S, Trubiani O, Caputi S, Sinjari B. AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules. 2020;25(3):609. PMID: 32019204. (AEDG peptide effects on neurogenic gene expression in human gingival mesenchymal stem cells; histone-binding proposed as the mechanism.)
8. Caputi S, Trubiani O, Sinjari B, Trofimova S, Diomede F, Linkova N, Diatlova A, Khavinson V. Effect of short peptides on neuronal differentiation of stem cells. Int J Immunopathol Pharmacol. 2019;33:2058738419828613. (Short peptide effects on stem-cell neuronal differentiation; Khavinson-collaborator authorship.)
9. Anisimov VN, Khavinson VK. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. PMID: 19830585. (Comprehensive Khavinson-group review of peptide bioregulator literature in aging research.)
10. Korkushko OV, Khavinson VK, Shatilo VB, Antonyk-Sheglova IA. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bull Exp Biol Med. 2011;151(3):366-369. (Long-term follow-up extension of the Korkushko/Khavinson elderly cohort.)
11. Khavinson V, Linkova N, Dyatlova A, Kuznik B, Umnov R. Peptides: Prospects for Use in the Treatment of COVID-19. Molecules. 2020;25(19):4389. (Khavinson-group review of short peptide bioregulator applications including AEDG / Epitalon mechanistic discussion.)
12. Anisimov SV, Bokeler KR, Khavinson VK, Anisimov VN. Studies of the effects of Vilon and Epitalon on gene expression in mouse heart using DNA microarray technology. Bull Exp Biol Med. 2002;133(3):293-299. (DNA microarray analysis of AEDG peptide effects on mouse cardiac gene expression — supporting the transcription-modulation hypothesis.)
13. Khavinson VK, Bondarev IE, Butyugov AA, Smirnova TD. Peptide promotes overcoming of the division limit in human somatic cell. Bull Exp Biol Med. 2004;137(5):503-506. (Parent Epithalon extension of fibroblast replicative capacity beyond the Hayflick limit.)
14. Fedoreyeva LI, Kireev II, Khavinson VK, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011;76(11):1210-1219. PMID: 22117545. (Mechanistic demonstration of short peptide nuclear penetration and specific DNA-binding — foundation of the chromatin-binding gene-expression mechanism hypothesis.)
15. Khavinson VK, Solovyov AY, Shataeva LK. Melting of DNA double strand after binding to geroprotective tetrapeptide. Bull Exp Biol Med. 2008;146(5):624-626. (Demonstrated DNA-melting effect of an AEDG-class tetrapeptide upon binding — biophysical basis for transcription modulation.)
16. Khavinson V, Shataeva L, Chernova A. DNA double-helix binds regulatory peptides similarly to transcription factors. Neuro Endocrinol Lett. 2005;26(3):237-241. (Theoretical and experimental case for short peptides as transcription-factor-like DNA binders — broader Khavinson hypothesis.)
17. Anisimov VN, Khavinson VK, Mikhalski AI, Yashin AI. Effect of synthetic dipeptide Vilon (Lys-Glu) on gene expression in mice. Mech Ageing Dev. 2001;122(13):1297-1304. (Sister Khavinson short-peptide dipeptide; gene-expression effects in mice — supports the transcription-modulation paradigm extended to AEDG.)
18. Khavinson VK, Linkova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM. Peptides tissue-specifically stimulate cell differentiation during their aging. Bull Exp Biol Med. 2012;153(1):148-151. (Tissue-specific differentiation effects of short peptides during cellular aging.)
19. Khavinson VK, Goncharova ND, Lapin BA. Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeys. Neuro Endocrinol Lett. 2001;22(4):251-254. (Aged rhesus monkey study — Epitalon restoration of disturbed neuroendocrine and circadian regulation.)
20. Araj S, et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. (2025). Independent replication of the core telomere-lengthening claim in modern human cell lines, with the mechanistic nuance that ALT pathway activation is observed specifically in cancer cells and not in normal cells.